Key facts
- Beaconcure’s last known valuation is $32.5M (Jan 2025).
- It has raised $20.7M across 3 recorded rounds; the latest was Early Stage VC ($15.0M) in Jan 2025.
- Notable investors include Innovation Authority, Keihanna Global Acceleration Program, Deloitte Launchpad, Green Innovations, NewVale Capital — 6 tracked in total.
- Beaconcure has filed 3 Form Ds with the SEC since 2021, most recently Jan 2025 ($15.0M sold to 5 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Beaconcure
Funding rounds
3 roundsAbout Beaconcure
Developer of statistical analysis validation software designed to improve mission-critical business challenges in drug development and regulatory approvals. The company's software offers query development, discovery, and fulfillment tools that use proprietary algorithms to generate data from evolving databases to save critical time, reduce human error, and accelerate regulatory approval to validate clinical trial data, enabling clients to gain meaningful value for their decision-making process.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2016
- Employees
- 36
- Website
- beaconcure.com/
- Ownership
- Privately Held (backing)
Beaconcure doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Beaconcure shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Beaconcure in its N-PORT filings yet. We sweep new filings monthly.